Associated tags: Brain, INP, CNRS, EUR, Aix-Marseille University, Neoplasm, Biotechnology, Other Health, Health, Pharmaceutical, Pharmaceutical industry, Therapy, Radiology, Medical Devices, Research, Oncology, Pharmacy, Science, Other Science
Locations: EUROPE, IRELAND, UNITED STATES, UNITED KINGDOM, NORTH AMERICA, KOCHI, PARIS, MARSEILLE, FR, FRANCE
Brain,
Scientific method,
Ionis Pharmaceuticals,
Pancreatic cancer,
Glioblastoma,
Novo Nordisk,
Viva Technology,
Clinical trial,
CNRS,
Cancer,
Biotechnology,
Pharmaceutical industry For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.
Key Points:
- For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.
- In the field of Health, Vect-Horus has been selected to present its VECTrans® technology, unique in Europe, which represents a breakthrough innovation in drug targeting to the brain and other pathological tissues (e.g.
- Vect-Horus Chief Scientific Officer Jean-Manuel Pean will take part in a roundtable, where he will present an overview of the Company and its pipeline.
- More details on the definite roundtable program will be announced closer to the event.
LDLR,
Small RNA,
Cancer,
Cell,
Central nervous system disease,
Tissue,
MDPI,
RNA,
GBM,
CNS,
PDAC,
Novo Nordisk,
Family,
Peptide,
Neoplasm,
Gene expression,
Glioblastoma,
Biotechnology,
Ionis,
Vaccine Because the LDLR is differentially expressed in organs and is overexpressed in many cancers including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), the results open new opportunities for delivery to different organs or tumors.
Key Points:
- Because the LDLR is differentially expressed in organs and is overexpressed in many cancers including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), the results open new opportunities for delivery to different organs or tumors.
- A vector belonging to this family of LDLR-targeting peptides is applied as a theragnostic agent for the diagnostic of GBM and PDAC.
- “These results reinforce the potential of vectors to significantly improve the transport and delivery of therapeutic and imaging agents to improve the diagnostic and treatment of cancer and CNS disorders,” said Alexandre Tokay co-founder and CEO of Vect-Horus.
- The study identified and optimized a family of peptide-based vectors that target the LDLR.
Retrieved on:
Tuesday, January 30, 2024
Mental Health,
Research,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
Traffic barrier,
Ionis Pharmaceuticals,
RNA,
Therapy,
Patient,
Central nervous system,
DSM-IV codes,
IONS,
Ionis,
Brain,
Medication,
Tissue,
Vaccine The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.
Key Points:
- The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.
- Ionis has an option to add additional targets to the license.
- Vect-Horus retains the rights to use its technology, for these specific targets, for all non-RNA-Targeted Medicines.
- “This license is aligned with our strategy of using our technology to deliver drug payloads, such as RNA-targeted therapeutics, to the brain and other tissues.
Retrieved on:
Thursday, January 11, 2024
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Clinical Trials,
Other Health,
Faculty,
Toxicology,
Pharmacy,
BBB,
Head,
SAB,
Pharmacokinetics,
Blood–brain barrier,
CNS Xavier Declèves to its scientific advisory board (SAB).
Key Points:
- Xavier Declèves to its scientific advisory board (SAB).
- Jean-Manuel Péan, Chief Scientific Officer of Vect-Horus commented, “We are pleased to welcome Xavier in our SAB.
- Declèves, our SAB now has a tremendous level of scientific expertise that will be instrumental in advancing our technology and programs.
- “ I'm delighted to join the Vect-Horus Advisory Board and share my expertise and ideas around targeting technologies dedicated to modern therapeutic modalities ” commented Xavier Declèves.
Oncology,
Medical Devices,
Health,
Other Health,
Radiology,
Biotechnology,
Senior,
Conditional sentence,
Novo Nordisk,
Therapy,
Pharmaceutical industry Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.
Key Points:
- Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.
- This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets .
- Novo Nordisk has an option to add additional targets to the license.
- We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments”.
Health,
Medical Devices,
Health Technology,
Other Health,
Radiology,
Pharmaceutical,
Biotechnology,
D.A.V. College Managing Committee,
University,
Jean-Manuel Thetis,
Publication,
Drug delivery,
Pharmacy,
Doctor of Philosophy,
Pharmaceutical industry VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.
Key Points:
- VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.
- In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
- Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our Chief Scientific Officer as he brings over 20 years of significant experience in the pharmaceutical industry.
- Dr Péan obtained his PhD in Pharmaceutical Sciences from Paris XI University.
Retrieved on:
Wednesday, January 20, 2021
Medical devices,
Finance,
Clinical trials,
Professional services,
Other Health,
Radiology,
Pharmaceutical,
Health,
Oncology,
Other Professional Services,
Nucleic acids,
Branches of biology,
Molecular biology,
Gene expression,
Biotechnology,
Small interfering RNA,
RNA,
Solid lipid nanoparticle,
Sense The first round, held in September 2020, raised 6.7 million and a second round in December 2020 added 5.3 million from private investors, bringing the total amount raised in these two rounds to 12 million.
Key Points:
- The first round, held in September 2020, raised 6.7 million and a second round in December 2020 added 5.3 million from private investors, bringing the total amount raised in these two rounds to 12 million.
- The health crisis has for the first time highlighted the enormous therapeutic potential (in terms of vaccination) of messenger RNAs (mRNAs) encapsulated in lipid nanoparticles.
- In contrast, antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) inhibit the expression of a particular gene and therefore the corresponding protein.
- The proof of concept of the technology has already been established in animal models using different vectorized molecules.
Retrieved on:
Tuesday, November 17, 2020
Medical devices,
Hospitals,
Clinical trials,
Biotechnology,
Other Health,
Radiology,
Health,
Pharmaceutical,
Oncology,
Medical physics,
Image processing,
Nuclear medicine,
Medical imaging,
Applied sciences VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS theragnostic agents.
Key Points:
- VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS theragnostic agents.
- CERIMED, also based in the Timone Aix-Marseille University Campus, has expertise in medical imaging techniques (PET, SPECT, etc.)
- and provides a complete platform of in vivo preclinical and clinical imaging entirely dedicated to R&D of innovative clinical imaging tools.
- CERIMED is very proud to announce the initiation of this collaboration with VECT-HORUS.
Retrieved on:
Tuesday, September 8, 2020
It will strengthen the company's equity capital, enabling it to develop its programs and the upcoming clinical trial of its first theragnostic agent (contraction of the terms "therapeutic" and "diagnostic").
Key Points:
- It will strengthen the company's equity capital, enabling it to develop its programs and the upcoming clinical trial of its first theragnostic agent (contraction of the terms "therapeutic" and "diagnostic").
- It will also enable the development of new conjugates associating the company's vectors with therapeutic biomolecules: antibodies, mRNAs and various antisense oligonucleotides, including siRNAs.
- Therefore, the vectorization potential of the VECTrans platform will be significantly enriched in order to achieve its targeted therapy objectives in multiple organs and indications.
- Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours.
Retrieved on:
Tuesday, December 11, 2018
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Key Points:
- Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- This deal was facilitated by Johnson & Johnson Innovation Limited.
- Vect-Horus has developed its VECTrans technology that facilitates the delivery of drugs or imaging agents into the brain.
- Under the terms of the agreement, Vect-Horus will receive payments for R&D costs and is eligible to receive payments for additional option exercise fees, development and sales milestones.
